Navigation Links
Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting

IRVINE, Calif. and LONDON--(BUSINESS WIRE)--Apr 16, 2007 - Somanta Pharmaceuticals (OTCBB:SMPM) today announced that data from its Alchemix program will be presented later today at the American Association for Cancer Research Annual Meeting in Los Angeles.

The poster presentation is entitled "Cytotoxicity of novel alkylating anthraquinones in cells with DNA Nucleotide Excision Repair and DNA Mismatch Repair defects," and focuses on structure-activity studies on the company's novel technology for targeting and irreversibly binding to DNA / DNA processing enzymes. The studies reported in the poster were conducted at the Institute for Cancer Therapeutics at the University of Bradford, Bradford, United Kingdom (www.cancer.Brad.ac.uk) under the collaborative research agreement announced previously.

Somanata recently announced the company had signed a letter of intent to be acquired by Access Pharmaceuticals, Inc, (OTCBB:ACCP) an emerging oncology-focused biopharmaceutical company based in Dallas, Texas.

About Somanta Pharmaceuticals

Somanta Pharmaceuticals, Inc. ("Somanta") is a specialty oncology company with particular focus on in-licensing anti-cancer agents with substantial clinical data supporting safety and efficacy. To date, the Company has successfully in-licensed the rights to four products, each with a different mode of action and targeting eleven different cancer types.

Certain statements contained herein are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statem ents include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Somanta's compounds under development in particular; the potential failure of Somanta's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Somanta's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Somanta's business, structure or projections; the development of competing products; uncertainties related to Somanta's dependence on third parties and partners; and those risks described in Somanta's filings with the SEC. Somanta disclaims any obligation to update these forward-looking statements.

Contact

Somanta Pharmaceuticals, Inc.
Terrance J. Bruggeman
Executive Chairman
949-706-3697
or
Agamemnon A. Epenetos
President and Chief Executive Officer
011-44 207 631 4868


'"/>




Related medicine technology :

1. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
Breaking Medicine News(10 mins):